SURGERY PARTNERS INC (SGRY) Fundamental Analysis & Valuation

NASDAQ:SGRY • US86881A1007

Current stock price

11.51 USD
+0.02 (+0.17%)
Last:

This SGRY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. SGRY Profitability Analysis

1.1 Basic Checks

  • In the past year SGRY was profitable.
  • SGRY had a positive operating cash flow in the past year.
  • SGRY had negative earnings in each of the past 5 years.
  • Each year in the past 5 years SGRY had a positive operating cash flow.
SGRY Yearly Net Income VS EBIT VS OCF VS FCFSGRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

1.2 Ratios

  • SGRY's Return On Assets of -0.96% is in line compared to the rest of the industry. SGRY outperforms 42.00% of its industry peers.
  • SGRY has a Return On Equity of -4.55%. This is comparable to the rest of the industry: SGRY outperforms 48.00% of its industry peers.
  • SGRY has a Return On Invested Capital (5.05%) which is comparable to the rest of the industry.
  • The Average Return On Invested Capital over the past 3 years for SGRY is below the industry average of 8.74%.
Industry RankSector Rank
ROA -0.96%
ROE -4.55%
ROIC 5.05%
ROA(3y)-1.09%
ROA(5y)-1.08%
ROE(3y)-4.85%
ROE(5y)-4.95%
ROIC(3y)5.12%
ROIC(5y)4.89%
SGRY Yearly ROA, ROE, ROICSGRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

1.3 Margins

  • SGRY's Operating Margin of 14.49% is amongst the best of the industry. SGRY outperforms 88.00% of its industry peers.
  • In the last couple of years the Operating Margin of SGRY has grown nicely.
  • With a Gross Margin value of 25.78%, SGRY perfoms like the industry average, outperforming 54.00% of the companies in the same industry.
  • In the last couple of years the Gross Margin of SGRY has remained more or less at the same level.
Industry RankSector Rank
OM 14.49%
PM (TTM) N/A
GM 25.78%
OM growth 3Y-0.58%
OM growth 5Y7.38%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5Y0.52%
SGRY Yearly Profit, Operating, Gross MarginsSGRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. SGRY Health Analysis

2.1 Basic Checks

  • SGRY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for SGRY has been increased compared to 1 year ago.
  • SGRY has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, SGRY has a worse debt to assets ratio.
SGRY Yearly Shares OutstandingSGRY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
SGRY Yearly Total Debt VS Total AssetsSGRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • Based on the Altman-Z score of 0.68, we must say that SGRY is in the distress zone and has some risk of bankruptcy.
  • SGRY has a worse Altman-Z score (0.68) than 73.00% of its industry peers.
  • SGRY has a debt to FCF ratio of 18.93. This is a negative value and a sign of low solvency as SGRY would need 18.93 years to pay back of all of its debts.
  • SGRY has a Debt to FCF ratio of 18.93. This is in the lower half of the industry: SGRY underperforms 64.00% of its industry peers.
  • SGRY has a Debt/Equity ratio of 2.10. This is a high value indicating a heavy dependency on external financing.
  • SGRY has a worse Debt to Equity ratio (2.10) than 74.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.1
Debt/FCF 18.93
Altman-Z 0.68
ROIC/WACC0.57
WACC8.79%
SGRY Yearly LT Debt VS Equity VS FCFSGRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • A Current Ratio of 1.87 indicates that SGRY should not have too much problems paying its short term obligations.
  • SGRY has a better Current ratio (1.87) than 79.00% of its industry peers.
  • SGRY has a Quick Ratio of 1.71. This is a normal value and indicates that SGRY is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.71, SGRY is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.87
Quick Ratio 1.71
SGRY Yearly Current Assets VS Current LiabilitesSGRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. SGRY Growth Analysis

3.1 Past

  • The earnings per share for SGRY have decreased strongly by -51.06% in the last year.
  • SGRY shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 52.38% yearly.
  • SGRY shows a small growth in Revenue. In the last year, the Revenue has grown by 6.24%.
  • The Revenue has been growing by 12.21% on average over the past years. This is quite good.
EPS 1Y (TTM)-51.06%
EPS 3Y52.38%
EPS 5YN/A
EPS Q2Q%-72.73%
Revenue 1Y (TTM)6.24%
Revenue growth 3Y9.22%
Revenue growth 5Y12.21%
Sales Q2Q%2.38%

3.2 Future

  • Based on estimates for the next years, SGRY will show a very strong growth in Earnings Per Share. The EPS will grow by 39.13% on average per year.
  • The Revenue is expected to grow by 8.14% on average over the next years. This is quite good.
EPS Next Y62.98%
EPS Next 2Y44.95%
EPS Next 3Y42.68%
EPS Next 5Y39.13%
Revenue Next Year3.61%
Revenue Next 2Y4.63%
Revenue Next 3Y5.91%
Revenue Next 5Y8.14%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SGRY Yearly Revenue VS EstimatesSGRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B 4B
SGRY Yearly EPS VS EstimatesSGRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

6

4. SGRY Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 25.02, the valuation of SGRY can be described as expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of SGRY indicates a somewhat cheap valuation: SGRY is cheaper than 62.00% of the companies listed in the same industry.
  • SGRY's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.89.
  • The Price/Forward Earnings ratio is 15.35, which indicates a correct valuation of SGRY.
  • SGRY's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. SGRY is cheaper than 71.00% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.19. SGRY is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 25.02
Fwd PE 15.35
SGRY Price Earnings VS Forward Price EarningsSGRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, SGRY is valued cheaply inside the industry as 82.00% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, SGRY is valued cheaply inside the industry as 87.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 7.62
EV/EBITDA 7.55
SGRY Per share dataSGRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 -20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • SGRY's earnings are expected to grow with 42.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.4
PEG (5Y)N/A
EPS Next 2Y44.95%
EPS Next 3Y42.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SGRY Dividend Analysis

5.1 Amount

  • No dividends for SGRY!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SGRY Fundamentals: All Metrics, Ratios and Statistics

SURGERY PARTNERS INC

NASDAQ:SGRY (3/30/2026, 11:00:01 AM)

11.51

+0.02 (+0.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-02
Earnings (Next)05-11
Inst Owners82.8%
Inst Owner Change2.21%
Ins Owners1.17%
Ins Owner Change1.19%
Market Cap1.49B
Revenue(TTM)3.31B
Net Income(TTM)-77.90M
Analysts81.11
Price Target19.73 (71.42%)
Short Float %17.94%
Short Ratio7.88
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-41.91%
Min EPS beat(2)-60.78%
Max EPS beat(2)-23.03%
EPS beat(4)1
Avg EPS beat(4)-21%
Min EPS beat(4)-60.78%
Max EPS beat(4)24.15%
EPS beat(8)4
Avg EPS beat(8)-6.88%
EPS beat(12)8
Avg EPS beat(12)176.88%
EPS beat(16)9
Avg EPS beat(16)102.65%
Revenue beat(2)1
Avg Revenue beat(2)-0.88%
Min Revenue beat(2)-1.9%
Max Revenue beat(2)0.14%
Revenue beat(4)1
Avg Revenue beat(4)-1.18%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)0.14%
Revenue beat(8)4
Avg Revenue beat(8)-0.24%
Revenue beat(12)4
Avg Revenue beat(12)-0.76%
Revenue beat(16)6
Avg Revenue beat(16)-0.79%
PT rev (1m)-24.02%
PT rev (3m)-25.61%
EPS NQ rev (1m)-536.4%
EPS NQ rev (3m)-536.4%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-2.95%
Revenue NQ rev (3m)-2.95%
Revenue NY rev (1m)-4.21%
Revenue NY rev (3m)-4.21%
Valuation
Industry RankSector Rank
PE 25.02
Fwd PE 15.35
P/S 0.45
P/FCF 7.62
P/OCF 5.43
P/B 0.87
P/tB N/A
EV/EBITDA 7.55
EPS(TTM)0.46
EY4%
EPS(NY)0.75
Fwd EY6.51%
FCF(TTM)1.51
FCFY13.13%
OCF(TTM)2.12
OCFY18.41%
SpS25.57
BVpS13.24
TBVpS-27.22
PEG (NY)0.4
PEG (5Y)N/A
Graham Number11.7
Profitability
Industry RankSector Rank
ROA -0.96%
ROE -4.55%
ROCE 6.39%
ROIC 5.05%
ROICexc 5.21%
ROICexgc 18.67%
OM 14.49%
PM (TTM) N/A
GM 25.78%
FCFM 5.91%
ROA(3y)-1.09%
ROA(5y)-1.08%
ROE(3y)-4.85%
ROE(5y)-4.95%
ROIC(3y)5.12%
ROIC(5y)4.89%
ROICexc(3y)5.3%
ROICexc(5y)5.11%
ROICexgc(3y)19.01%
ROICexgc(5y)18.72%
ROCE(3y)6.48%
ROCE(5y)6.19%
ROICexgc growth 3Y2.9%
ROICexgc growth 5Y5.08%
ROICexc growth 3Y1.35%
ROICexc growth 5Y9.67%
OM growth 3Y-0.58%
OM growth 5Y7.38%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5Y0.52%
F-Score5
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 2.1
Debt/FCF 18.93
Debt/EBITDA 5.5
Cap/Depr 44.72%
Cap/Sales 2.38%
Interest Coverage 1.87
Cash Conversion 41.85%
Profit Quality N/A
Current Ratio 1.87
Quick Ratio 1.71
Altman-Z 0.68
F-Score5
WACC8.79%
ROIC/WACC0.57
Cap/Depr(3y)59.72%
Cap/Depr(5y)61.53%
Cap/Sales(3y)2.84%
Cap/Sales(5y)2.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.06%
EPS 3Y52.38%
EPS 5YN/A
EPS Q2Q%-72.73%
EPS Next Y62.98%
EPS Next 2Y44.95%
EPS Next 3Y42.68%
EPS Next 5Y39.13%
Revenue 1Y (TTM)6.24%
Revenue growth 3Y9.22%
Revenue growth 5Y12.21%
Sales Q2Q%2.38%
Revenue Next Year3.61%
Revenue Next 2Y4.63%
Revenue Next 3Y5.91%
Revenue Next 5Y8.14%
EBIT growth 1Y1.03%
EBIT growth 3Y8.59%
EBIT growth 5Y20.49%
EBIT Next Year41.41%
EBIT Next 3Y18.21%
EBIT Next 5YN/A
FCF growth 1Y-6.72%
FCF growth 3Y35.74%
FCF growth 5Y-0.84%
OCF growth 1Y-8.6%
OCF growth 3Y19.98%
OCF growth 5Y2.13%

SURGERY PARTNERS INC / SGRY Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SURGERY PARTNERS INC?

ChartMill assigns a fundamental rating of 4 / 10 to SGRY.


What is the valuation status for SGRY stock?

ChartMill assigns a valuation rating of 6 / 10 to SURGERY PARTNERS INC (SGRY). This can be considered as Fairly Valued.


How profitable is SURGERY PARTNERS INC (SGRY) stock?

SURGERY PARTNERS INC (SGRY) has a profitability rating of 4 / 10.


What is the financial health of SURGERY PARTNERS INC (SGRY) stock?

The financial health rating of SURGERY PARTNERS INC (SGRY) is 2 / 10.


What is the earnings growth outlook for SURGERY PARTNERS INC?

The Earnings per Share (EPS) of SURGERY PARTNERS INC (SGRY) is expected to grow by 62.98% in the next year.